Delayed post-ischaemic administration of xenon reduces brain damage in a rat model of global ischaemia

References

• Eger EI, Larson CP. Anaesthetic solubility in blood and tissues: Values and significance. British Journal of Anaesthesia 1964;36:140–149
   PubMed Web of Science ®Google Scholar
• Dickinson R, Peterson BK, Banks P, Simillis C, Martin JC, Valenzuela CA, Maze M, Franks NP. Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor by the anesthetics xenon and isoflurane: Evidence from molecular modeling and electrophysiology. Anesthesiology 2007;107:756–767
   PubMed Web of Science ®Google Scholar
• Franks NP, Dickinson R, de Sousa SLM. How does xenon produce anaesthesia? Nature 1998;396:324
   PubMed Web of Science ®Google Scholar
• Jevtović-Todorović V, Todorović SM, Mennerick S, Powell S, Dikranian K, Benshoff N, Zorumski CF, Olney JW. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nature Medicine 1998;4:460–463
   PubMed Web of Science ®Google Scholar
• Dohmen C, Kumura E, Rosner G, Heiss WD, Graf R. Extracellular correlates of glutamate toxicity in short-term cerebral ischemia and reperfusion: A direct in vivo comparison between white and gray matter. Brain Research 2005;1037:43–51
   PubMedGoogle Scholar
• Wilhelm S, Ma D, Maze M, Franks NP. Effects of Xenon on in vitro and in vivo models of neuronal injury. Anesthesiology 2002;96:1485–1491
   PubMed Web of Science ®Google Scholar
• Parsons CG, Danysz W, Quack G. Glutamate in CCNS disorders as a target for drug development: An update. Drug News & Perspectives 1198;11:523–569
   Google Scholar
• Ferrer-Montiel AV, Sun W, Montal M. Molecular design of the N-methyl-D-aspartate receptor binding site for phencyclidine and dizolcipine. Proceedings of the National Academy of Sciences 1995;92:8021–8025
   PubMed Web of Science ®Google Scholar
• Abraini Jacques H, David Hélène N, Marc L. Potentially neuroprotective and therapeutic properties of nitrous oxide and xenon. Annals of the New York Academy of Sciences 2005;1053:289–300
   PubMedGoogle Scholar
• Derwall M, Timper A, Kottmann K, Rossaint R, Fries M. Neuroprotective effects of the inhalational anesthetics isoflurane and xenon after cardiac arrest in pigs. Critical Care Medicine 2008;36:S492–S495
   Google Scholar
• Schmidt M, Marx T, Glöggl E, Reinelt H, Schirmer U. Xenon attenuates cerebral damage after ischemia in pigs. Anesthesiology 2005;102:929–936
   PubMedGoogle Scholar
• David HN, Haelewyn B, Rouillon C, Lecoq M, Chazalviel L, Apiou G, Risso JJ, Lemaire M, Abraini JH. Neuroprotective effects of xenon: A therapeutic window of opportunity in rats subjected to transient cerebral ischemia. The FASEB Journal 2008;22:1275–1286
   PubMed Web of Science ®Google Scholar
• David HN, Leveille F, Chazalviel L, MacKenzie ET, Buisson A, Lemaire M, Abraini JH. Reduction of ischemic brain damage by nitrous oxide and xenon. The FASEB Journal 2003;23:1168–1173
   Google Scholar
• Homi HM, Yokoo N, Ma D, Warner DS, Franks NP, Maze M, Grocott HP. The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice. Anesthesiology 2003;99:876–881
   PubMedGoogle Scholar
• Dingley J, Tooley J, Porter H, Thoresen M. Xenon provides short-term neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke 2006;37:501–506
   PubMed Web of Science ®Google Scholar
• Yang T, Zhuang L, Rei Fidalgo AM, Petrides E, Terrando N, Wu X, Sanders RD, Robertson NJ, Johnson MR, Maze M, et al. Xenon and sevoflurane provide analgesia during labor and fetal brain protection in a perinatal rat model of hypoxia-ischemia. PLoS One 2012;7:e37020
   PubMed Web of Science ®Google Scholar
• Hobbs C, Thoresen M, Tucker A, Aquilina K, Chakkarapani E, Dingley J. Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. Stroke 2008;39:1307–1313
   PubMed Web of Science ®Google Scholar
• Martin JL, Ma D, Hossain M, Xu J, Sanders RD, Franks NP, Maze M. Asynchronous administration of xenon and hypothermia significantly reduces brain infarction in the neonatal rat. British Journal of Anaesthesia 2007;98:236–240
   PubMed Web of Science ®Google Scholar
• Hainsworth Atticus H, Markus HS. Do in vivo experimental models reflect human cerebral small vessel disease? A systematic review. Journal of Cerebral Blood Flow & Metabolism 2008;28:1877–1891
   PubMedGoogle Scholar
• Farkas E, Luiten PGM, Bari F. Permanent, bilateral common carotid artery occlusion in the rat: A model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Research Reviews 2007;54:162–180
   PubMedGoogle Scholar
• Ginsberg MD, Busto R. Rodent models of cerebral ischemia. Stroke 1989;20:1627–1642
   PubMed Web of Science ®Google Scholar
• Ulrich PT, Kroppenstedt S, Heimann A, Kempski O. Laser-Doppler Scanning of local cerebral blood flow and reserve capacity and testing of motor and memory functions in a chronic 2-vessel occlusion model in rats. Stroke 1998;29:2412–2420
   PubMedGoogle Scholar
• Tsuchiya M, Sako K, Yura S, Yonemasu Y. Cerebral blood flow and histopathological changes following permanent bilateral carotid artery ligation in Wistar rats. Experimental Brain Research 1992;89:87–92
   PubMed Web of Science ®Google Scholar
• Marosi M, Rákos G, Robotka H, Németh H, Sas K, Kis Z, Farkas T, Lür G, Vécsei L, Toldi J. Hippocampal (CA1) activities in Wistar rats from different vendors: Fundamental differences in acute ischemia. Journal of Neuroscience Methods 2006;156:231–235
   PubMed Web of Science ®Google Scholar
• Wolfrum S, Pierau C, Radke PW, Schunkert H, Kurowski V. Mild therapeutic hypothermia in patients after out-of-hospital cardiac arrest due to acute ST-segment elevation myocardial infarction undergoing immediate percutaneous coronary intervention. Critical Care Medicine 2008;36:1780–1786
   PubMed Web of Science ®Google Scholar
• David HN, Ansseau M, Lemaire M, Abraini JH. Nitrous oxide and xenon prevent amphetamine-induced carrier-mediated dopamine release in a memantine-like fashion and protect against behavioral sensitization. Biological Psychiatry 2006;60:49–57
   PubMedGoogle Scholar
• Haelewyn B, David HN, Rouillon C, Chazalviel L, Lecocq M, Risso JJ, Lemaire M, Abraini JH. Neuroprotection by nitrous oxide: Facts and evidence. Critical Care Medicine 2008;36:2651–2659
   PubMedGoogle Scholar
• Jevtović-Todorović V, Todorović SM, Mennerick S, Powell S, Dikranian K, Benshoff N, Zorumski CF, Olney JW. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nature Medicine 1998;4:460–463
   PubMed Web of Science ®Google Scholar
• Nagata A, Nakao Si S, Nishizawa N, Masuzawa M, Inada T, Murao K, Miyamoto E, Shingu K. Xenon inhibits but N2O enhances ketamine-induced c-Fos expression in the rat posterior cingulate and retrosplenial cortices. Anesthesia & Analgesia 2001;92:362–368
   PubMed Web of Science ®Google Scholar
• Thoresen M, Bågenholm R, Løberg EM, Apricena F, Kjellmer I. Posthypoxic cooling of neonatal rats provides protection against brain injury. Archives of Disease Childhood: Fetal & Neonatal Edition 1996;74:F3–F9
   PubMed Web of Science ®Google Scholar
• Zhang W, Hart J, McLeod HL, Wang HL. Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms. American Journal of Clinical Pathology 2005;124:11–19
   PubMedGoogle Scholar
• Ma D, Hossain M, Chow A, Arshad M, Battson RM, Sanders RD, Mehmet H, Edwards AD, Franks NP, Maze M. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Annals of Neurology 2005;58:182–193
   PubMed Web of Science ®Google Scholar
• David HN, Haelewyn B, Rouillon C, Lecoq M, Chazalviel L, Apiou G, Risso JJ, Lemaire M, Abraini JH. Neuroprotective effects of xenon: A therapeutic window of opportunity in rats subjected to transient cerebral ischemia. The FASEB Journal 2008;22:1275–1286
   PubMed Web of Science ®Google Scholar
• Rogers A, Schmuck G, Scholz G, Williams DC. c-fos mRNA expression in rat cortical neurons during glutamate-mediated excitotoxicity. Toxicological Sciences 2004;82:562–569
   PubMedGoogle Scholar
• Griffiths R, Grieve A, Scollon J, Scott M, Williams C, Meredith C. Preliminary evaluation of an in vitro test for assessment of excitotoxicity by measurement of early gene (c-fos mRNA) levels. Toxicology in Vitro 2000;14:447–458
   PubMedGoogle Scholar
• Kumar K, Wu X, Evans AT. Expression of c-fos and fos-B proteins following transient forebrain ischemia: Effect of hypothermia. Molecular Brain Research 1996;42:337–343
   PubMedGoogle Scholar
• Mancuso A, Derugin N, Hara K, Sharp FR, Weinstein PR. Mild hypothermia decreases the incidence of transient ADC reduction detected with diffusion MRI and expression of c-fos and hsp70 mRNA during acute focal ischemia in rats. Brain Research 2000;887:34–45
   PubMedGoogle Scholar
• Romanic AM, Madri JA. Extracellular matrix-degrading proteinases in the nervous system. Brain Pathology 1994;4:145–156
   PubMed Web of Science ®Google Scholar
• Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH. Role for Matrix Metalloproteinase 9 after focal cerebral ischemia[colon] effects of gene knockout and enzyme inhibition with BB-94. Journal of Cerebral Blood Flow & Metabolism 2000;20:1681–1689
   PubMed Web of Science ®Google Scholar
• Jiang X-F, Namura S, Nagata I. Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice. Neuroscience Letters 2001;305:41–44
   PubMed Web of Science ®Google Scholar
• Chen W, Hartman R, Ayer R, Marcantonio S, Kamper J, Tang J, Zhang JH. Matrix metalloproteinases inhibition provides neuroprotection against hypoxia-ischemia in the developing brain. Journal of Neurochemistry 2009;111:726–736
   PubMed Web of Science ®Google Scholar
• Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of Matrix Metalloproteinase-9 reduces infarct size. Stroke 1998;29:1020–1030
   PubMed Web of Science ®Google Scholar
• Kelly PJ, Morrow JD, Ning M, Koroshetz W, Lo EH, Terry E, Milne GL, Hubbard J, Lee H, Stevenson E, et al. Oxidative stress and Matrix Metalloproteinase-9 in acute ischemic stroke. Stroke 2008;39:100–104
   PubMed Web of Science ®Google Scholar
• Ramos-Fernandez M, Bellolio MF, Stead LG. Matrix Metalloproteinase-9 as a marker for acute ischemic stroke: A systematic review. Journal of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke Association 2011;20:47–54
   PubMed Web of Science ®Google Scholar
• Gawlak M, Górkiewicz T, Gorlewicz A, Konopacki FA, Kaczmarek L, Wilczynski GM. High resolution in situ zymography reveals matrix metalloproteinase activity at glutamatergic synapses. Neuroscience 2009;158:167–176
   PubMedGoogle Scholar
• Michaluk P, Mikasova L, Groc L, Frischknecht R, Choquet D, Kaczmarek L. Matrix Metalloproteinase-9 controls NMDA receptor surface diffusion through Integrin Ξ21 signaling. The Journal of Neuroscience 2009;29:6007–6012
   PubMedGoogle Scholar
• David HN, Leveille F, Chazalviel L, MacKenzie ET, Buisson A, Lemaire M, Abraini JH. Reduction of ischemic brain damage by nitrous oxide and xenon. Journal of Cerebral Blood Flow & Metabolism 2003;23:1168–1173
   PubMedGoogle Scholar
• Ma D, Wilhelm S, Maze M, Franks NP. Neuroprotective and neurotoxic properties of the inert gas, xenon. British Journal of Anaesthesia 2002;89:739–746
   PubMed Web of Science ®Google Scholar